Schistosomiasis - Pipeline Insight, 2024

This “Schistosomiasis - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Schistosomiasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Schistosomiasis Understanding

Schistosomiasis: Overview

Schistosomiasis, also known as bilharzia, is a disease caused by parasitic worms. Although the worms that cause schistosomiasis are not found in the United States, people are infected worldwide. In terms of impact this disease is second only to malaria as the most devastating parasitic disease. Schistosomiasis is considered one of the neglected tropical diseases (NTDs).The parasites that cause schistosomiasis live in certain types of freshwater snails. The infectious form of the parasite, known as cercariae, emerge from the snail into the water. You can become infected when your skin comes in contact with contaminated freshwater. Most human infections are caused by Schistosoma mansoni, S. haematobium, or S. japonicum.

Schistosomiasis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Schistosomiasis pipeline landscape is provided which includes the disease overview and Schistosomiasis treatment guidelines. The assessment part of the report embraces, in depth Schistosomiasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Schistosomiasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Schistosomiasis R&D. The therapies under development are focused on novel approaches to treat/improve Schistosomiasis.

Schistosomiasis Emerging Drugs Chapters

This segment of the Schistosomiasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Schistosomiasis Emerging Drugs

Praziquantel paediatric formulation: Merck Praziquantel paediatric formulation is being developed by Pediatric Praziquantel Consortium in association with Merck. A confirmatory Phase III trial is ongoing in Côte d’Ivoire and Kenya. This study is an open-label, efficacy and safety trial of Levo-Praziquantel 150mg in Schistosoma-infected children 3 months to 6 years of age, including a 2:1 randomized, controlled cohort of Schistosoma mansoni-infected children 4 to 6 years of age treated with L-PZQ ODT or commercialpraziquantel.

Sm 14: Orygen BiotecnologiaSm 14, a recombinant fatty acid binding protein (FABP) antigen vaccine for the treatment of Schistosomiasis. Currently, it is in phase II stage of clinical trial evaluation.

Schistosomiasis: Therapeutic Assessment

This segment of the report provides insights about the different Schistosomiasis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Schistosomiasis

There are approx. 3+ key companies which are developing the therapies for Schistosomiasis. The companies which have their Schistosomiasis drug candidates in the most advanced stage, i.e. phase III include, Merck.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Schistosomiasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Schistosomiasis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Schistosomiasis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Schistosomiasis drugs.

Schistosomiasis Report Insights

• Schistosomiasis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Schistosomiasis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Schistosomiasis drugs?
• How many Schistosomiasis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Schistosomiasis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Schistosomiasis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Schistosomiasis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Merck
• Orygen Biotecnologia
• Ocean Biomedical
• BioDiem

Key Products

• Praziquantel paediatric formulation
• Sm 14
• Schistosomiasis vaccine

Research programme: anti-infectives


This product will be delivered within 1-3 business days.